Roadmap to Clinical Use of Gold Nanoparticles for Radiation Sensitization

• Published in: International journal of radiation oncology, biology, physics Vol. 94; no. 1; pp. 189 - 205
• Main Authors: Schuemann, Jan, PhD, Berbeco, Ross, PhD, Chithrani, Devika B., PhD, Cho, Sang Hyun, PhD, Kumar, Rajiv, PhD, McMahon, Stephen J., PhD, Sridhar, Srinivas, PhD, Krishnan, Sunil, MD
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 2016
• Subjects: Animals; Blood Circulation Time; CHARGED PARTICLES; Chemistry, Pharmaceutical - methods; CLINICAL TRIALS; GOLD; Gold - chemistry; Gold - pharmacokinetics; Gold - therapeutic use; Hematology, Oncology and Palliative Medicine; Humans; IN VITRO; IN VIVO; Metal Nanoparticles - therapeutic use; Monte Carlo Method; NANOPARTICLES; NEOPLASMS; Neoplasms - blood supply; Neoplasms - radiotherapy; PARTICLE SIZE; Photons - therapeutic use; Proton Therapy; Radiation Tolerance; Radiation-Sensitizing Agents - chemistry; Radiation-Sensitizing Agents - pharmacokinetics; Radiation-Sensitizing Agents - therapeutic use; Radiology; RADIOLOGY AND NUCLEAR MEDICINE; RADIOSENSITIVITY; RADIOSENSITIZERS; RADIOTHERAPY; Surface Properties
• ISSN: 0360-3016; 1879-355X
• DOI: 10.1016/j.ijrobp.2015.09.032

The past decade has seen a dramatic increase in interest in the use of gold nanoparticles (GNPs) as radiation sensitizers for radiation therapy. This interest was initially driven by their strong absorption of ionizing radiation and the resulting ability to increase dose deposited within target volumes even at relatively low concentrations. These early observations are supported by extensive experimental validation, showing GNPs' efficacy at sensitizing tumors in both in vitro and in vivo systems to a range of types of ionizing radiation, including kilovoltage and megavoltage X rays as well as charged particles. Despite this experimental validation, there has been limited translation of GNP-mediated radiation sensitization to a clinical setting. One of the key challenges in this area is the wide range of experimental systems that have been investigated, spanning a range of particle sizes, shapes, and preparations. As a result, mechanisms of uptake and radiation sensitization have remained difficult to clearly identify. This has proven a significant impediment to the identification of optimal GNP formulations which strike a balance among their radiation sensitizing properties, their specificity to the tumors, their biocompatibility, and their imageability in vivo. This white paper reviews the current state of knowledge in each of the areas concerning the use of GNPs as radiosensitizers, and outlines the steps which will be required to advance GNP-enhanced radiation therapy from their current pre-clinical setting to clinical trials and eventual routine usage.